Bifogade filer
PAXMAN Q4 2021 ENG
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Paxman’s strongest quarter to date
October–December 2021
The Group’s total sales amounted to 29.3 (18.2) MSEK for the period October–December, an increase of 61%. The revenues in the US have seen a significant growth rate of 48% compared to Q4 2020.
The EBITDA for Q4 amounted to 4.2 (-3.3) MSEK, and for the same period the PAXMAN Group achieved a negative net result of -1.3 MSEK (compared to last year’s -11.0 MSEK).
The corresponding earnings per share were -0.07 (-0.69) SEK. Cash flow before financing activities totalled -4.7 (-2.7) MSEK for the period October–December, of which investments in fixed assets -5.7 (-1.0) MSEK.
January–December 2021
Total 2021 sales were 96.2 (78.0) MSEK, an increase of 23% compared to previous year. EBITDA amounted to 2.8 (-1.0) MSEK. Net result for the year reached -12.8 (-19.2) MSEK, and earnings per share were -0.73 (-1.20) SEK. Cash flow before financing activities totalled -28.6 (-14.8) MSEK, of which investments in fixed assets -23.8 (-6.3) MSEK.
In 2021 a total of 401 scalp cooling systems were installed around the world, with an additional 167 systems in the order book as of 23 February 2022.
Significant developments in Q4
- In November, Paxman announced that the US Centers for Medicare & Medicaid Services (CMS) has reassigned payment for scalp cooling for Medicare claims filed using CPT code 0662T to New Technology APC 1520 with a National Average Payment of 1,850.50 USD, effective January 1, 2022.
- In November, the company announced the opening of a clinical trial with National University Hospital, Singapore, in collaboration with The N.1 Institute for Health, National University of Singapore. The study aims to investigate the safety and tolerability of limb cryocompression in preventing of Chemotherapy-induced Peripheral Neuropathy (CIPN) via the newly developed Paxman Cryocompression System (PCCS) in healthy subjects and cancer patients.
- In December, the company announced that it had completed a direct share issue of 1,400.000 shares, through which the company receives SEK 77 million before transaction costs. The proceeds from the share issue will be used to strengthen the company’s financial position and the continued work to execute on its commercialisation strategy, including launch of a new buy-and-bill business model in the United States to enable reimbursement.
Significant developments after year-end
- In February, Paxman launched Scalp Cooling Study Library, a digital library website with at wealth of scalp cooling clinical research studies and data. The Library was developed as a way of increasing access to information on scalp cooling as a whole, with the aim of improving the knowledge base of global cancer care providers.
- In February, Paxman appointed Rocol International SAS as the company’s exclusive distribution partner for the new territory of Colombia. As an established medical device distributor in the oncology space, Rocol International SAS is well positioned to introduce scalp cooling to the Colombian market from its headquarters in Barranquilla, the capital of Colombia’s Atlántico Department.